22 November 2022



The Nifty previous session 0.46% up at 18244.20. It opened on a weaker note and remained range-bound with a positive bias towards ending in green. Chart pattern suggesting the Nifty coming down to 18050-18000 is most likely. Retracement may again find buyers on dips around 18000 levels. Range bound oscillation in the price band of 18000-18300 is most likely.

On the Nifty hourly chart, direction of the leading indicators suggesting the benchmark index may remain stuck in the price band of 18000-18300. Staying cautious on rise is advised.

Nifty patterns on multiple periods suggesting; closing below 18300 for the second consecutive session is worrisome. Index majors looks extremely overbought, hence retracement is likely.

Nifty Crucial Supports & Resistances-Supports- 18050, 18000 Resistances- 18300, 18350

Open Positional Calls-

T+15 INST POSITIONAL SELL-

|Fut Segment| TVS MOTOR @ 1100-1110, TGT- 1010, Closing SL- above 1160

T+15 INST POSITIONAL SELL-

|Fut Segment| ITC @ 350-355, TGT- 325, Closing SL- above 370

T+15 INST POSITIONAL SELL-

|Fut Segment| HDFC @ 2640-2660, TGT-2520, Closing SL- above 2730

T+15 INST POSITIONAL BUY-

|Cash Segment| PAGE IND @ 46500-45500, TGT- 49500, Closing SL- below 44000

T+7 BUY-

|Options Segment| HDFC 29DEC-2600-PE @ 37-35, TGT- 52, Closing SL- below 28

T+15 POSITIONAL SELL-

|Fut Segment| DLF @ 390-395, TGT- 365, Closing SL- above 410


STST-

|Cash Segment| M&M @ 1230, TGT- 1260, Closing SL- below 1215

Key Contents	Page No.
Domestic News	4







Market in Retrospect

Indian stock benchmarks snapped a three-day losing streak to end higher on Tuesday, aided by gains in metal, and information & technology stocks.

Nifty index ended 0.46% higher at 18,244. The broader markets represented by the Nifty 500 Index ended 0.36% higher, ending at 15,509. Among the sectorial indices, Nifty PSU Bank was the top gainer gaining by 1.66%, followed by Nifty Metal 0.89%. Nifty Realty was the only loser, losing by 1.22%.

Indusind Bank was the top gainer, gaining by 2.67%, followed by JSW Steel and NTPC which gaining by 1.68% & 1.61%. BPCL was the top loser, losing by 1.11%, followed by Nestle India and Power Grid which losing by 0.75% & 0.57%.

NIFTY Top Gainers

Market Turnover (In Crore) 22-11-2022						
Name		Last	Previous			
NSE Cash		48423.21	46489.62			
NSE F&O	105	526564.54	8704605.87			
BSE Cash		3,577.15	3,030.80			
BSE F&O		*NA	103.09			
FII Derivatives Flow (In Crore) 22-11-2022						
Instrument	Purchase	Sa	le Net			
Index Future	5571.41	4050.	1521.35			
Index Option	575704.99	578291.	22 2586.23			
Stock Future	51694.08	50745.	948.53			
Stock Option	9403.09	9584.	180.97			
Institutional Flow (In Crore) 22-11-2022						
Institution	Purchase	Sa	ile Net			
FII	7288.52	7986.	697.83			
DII	5334.42	4698.	03 636.39			


Name	%1D	%5D	Day Vol	Avg 5 Day Vol			
Indusind Bank	2.67	1.44	3927395	2107878			
muusmu bank	2.07	1.44	3927393	210/8/8			
JSW Steel	1.68	1.95	2421572	1621148			
NTPC	1.61	2.93	15198091	12076590			
HDFC Life	1.43	1.32	2913409	2474033			
Ultratech Cement	1.31	1.74	393509	335182			
NIFTY Top Losers							
Name	%1D	%5D	Day Vol	Avg 5 Day Vol			
Kotak Bank	0.22	1.43	1166755	3260253			
Bharti Airtel	0.42	1.48	7601660	5430732			
Power Grid	0.57	0.83	3274834	6761194			
Nestle India	0.75	2.20	47422	39686			
BPCL	1.11	0.66	3735515	2251584			
Bulk and Block Deals							
https://www.nseindia	a.com/pi	oducts/co	ontent/equities/e	quities/bulk.htm			

https://www.nseindia.com/products/content/equities/equities/bulk.htm http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx





Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	61418.96	274.12	0.45	0.73	3.56	4.50	5.05
Nifty	18244.20	84.25	0.46	0.87	3.80	4.31	4.75
BSE M Cap	25217.18	120.33	0.48	1.10	1.66	2.86	0.09
BSE S Cap	28723.25	29.34	0.10	1.15	0.55	3.16	2.78
Nifty MC 100	31070.00	168.50	0.55	1.06	1.23	2.27	2.43
BSE Auto	29241.33	105.18	0.36	2.94	0.46	0.27	13.93
BSE Capgoods	33506.16	179.39	0.54	1.17	5.57	7.62	19.85
BSE FMCG	15965.53	91.31	0.58	0.18	1.23	2.20	13.93
BSE Metal	19790.19	160.04	0.82	2.61	7.27	7.71	3.67
BSE Oil&Gas	19623.35	7.26	0.04	2.68	5.28	0.98	9.50
BSE Healthcare	23375.45	51.76	0.22	1.71	0.04	3.35	5.17
BSE Power	4579.74	47.38	1.02	5.50	3.11	8.69	30.60
BSE Realty	3487.40	36.02	1.02	3.29	2.60	0.34	11.72
BSE ConsDur	41082.04	271.66	0.67	1.58	1.25	1.54	5.03
BSE Bank	48503.69	86.23	0.18	0.23	3.53	10.49	14.56
BSE IT	29598.89	219.33	0.75	1.33	3.56	1.36	14.55

Bond Markets							
Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	3.79	0.04	1.03	0.48	10.18	25.64	133.28
UK	3.18	0.00	0.09	3.40	21.49	26.61	241.16
Brazil	6.28	0.01	0.13	1.32	5.10	8.19	35.21
Japan	0.25	0.00	0.81	1.63	2.73	12.16	232.00
Australia	3.59	0.01	0.22	4.39	14.41	2.13	100.45
India	7.29	0.03	0.45	0.08	2.98	0.25	14.74
Switzerland	1.02	0.02	1.60	5.56	25.35	38.45	666.11
Germany	2.00	0.00	0.15	5.27	17.38	52.91	763.46

Currency							
Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	81.67	0.17	0.21	0.70	1.25	2.21	8.90
USD Index	107.32	0.51	0.47	0.86	4.19	1.58	11.16
YUAN	7.14	0.03	0.41	1.27	1.77	4.04	10.53
GBP	1.19	0.01	0.48	0.13	5.34	0.96	11.32
EUR	1.03	0.00	0.45	0.59	4.19	3.47	8.45
YEN	141.17	0.97	0.69	1.34	5.48	2.61	18.62

Freight							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	1177.00	12.00	1.01	11.17	35.29	7.32	55.50
Baltic Dirty	2459.00	94.00	3.97	25.40	41.57	58.85	222.28
SG Dubai HY	25.48	2.40	10.40	18.79	23.39	24.23	638.55

Global Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	33700.28	45.41	0.13	0.49	8.42	1.93	5.39
Nasdaq	11024.51	121.55	1.09	1.53	1.52	10.96	30.47
S&P 500	3949.94	15.40	0.39	0.18	5.25	4.54	15.65
FTSE100	7429.12	52.05	0.71	0.81	6.59	1.39	2.39
CAC40	6640.02	6.42	0.10	0.01	10.03	4.11	6.53
DAX	14421.92	44.26	0.31	0.32	13.30	9.02	10.50
Mexico IPC	51569.72	208.85	0.41	0.75	9.44	6.41	1.49
Brazil Bovespa	109748.2	878.01	0.81	2.23	8.49	0.68	7.47
Russian RTS	1136.71	14.21	1.27	1.99	8.18	3.18	30.19
Japan Nikkei	28115.74	170.95	0.61	0.45	4.56	2.36	5.57
Hang Seng	17424.41	231.50	1.31	5.01	7.48	11.36	30.17
Taiwan Index	14542.20	92.81	0.64	0.03	13.44	4.61	18.32
Shanghai Comp	3088.94	3.90	0.13	1.44	1.65	5.76	13.77
KOSPI	2405.27	14.23	0.59	3.03	8.68	2.32	20.18
Malaysia KLCI	1441.29	6.67	0.46	1.55	0.35	3.10	5.60
Jakarta Comp	7030.59	32.66	0.46	0.07	0.18	1.09	4.57
Philippine SE	6429.65	26.41	0.41	0.17	7.46	4.10	11.71
Thai Exch	1615 33	3 53	0.22	0.86	1 51	0.03	2 07

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	80.62	0.59	0.74	7.24	5.20	10.64	5.06
BRENT Crude	88.09	0.62	0.71	6.17	3.58	6.25	20.07
Natural Gas	6.50	0.27	3.98	7.82	18.90	33.68	52.51

LME							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1747.71	9.78	0.56	1.75	5.44	0.66	3.15
Silver(\$/Ounce)	21.21	0.36	1.74	1.65	9.23	11.71	12.28
Aluminium	2355.55	49.96	2.08	2.96	7.63	1.60	12.36
Copper	7840.50	202.00	2.51	6.17	1.57	3.21	19.61
Zinc	2890.25	132.75	4.39	8.36	3.01	18.54	11.95
Lead	2082.25	58.80	2.75	5.12	8.93	2.17	6.12

Agro Commodities							
Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	161.35	0.95	0.59	1.16	13.16	25.46	30.32
Cotton	80.47	0.69	0.86	7.47	2.44	27.66	10.08
Sugar	19.86	0.00	0.00	2.12	8.05	10.83	5.98
Wheat	817.50	0.75	0.09	3.60	5.98	1.58	3.40
Soybean	1434.50	2.25	0.16	1.56	2.14	0.52	14.23



Dr Reddy's Laboratories among other generic pharma companies in US to face antitrust litigation

An antitrust litigation was filed against several generic pharmaceutical companies including Dr Reddy's Laboratories Ltd, Celgene and Bristol Myers Squibb in the US on Tuesday. Dr Reddy's Laboratories Ltd stated in a regulatory filing that a complaint was filed on November 18, 2022, in the District of New Jersey, USA, and it along with other generic pharmaceutical firms have been named as defendants. Revlimid is a prescription medicine, used to treat adults with multiple myeloma (MM) in combination with dexamethasone, or as maintenance treatment after a type of stem cell transplant that uses an individual's own stem cells. The complaint seeks damages for purported overpayments and equitable relief.

PFC Consulting invites bids for supply of 4,500 MW power to state utilities

State-owned PFC Consulting Ltd has invited bids for supply of 4,500 MW power for five years beginning April 2023 to different utilities in states, including Delhi, Maharasthra, Madhya Pradesh, Gujarat and Tamil Nadu. The document seeking request for proposal floated by PFC Consulting -- an arm of Power Finance Corporation -- also showed that five utilities have evinced interest for procuring as much as 3910 MW. The PFC Consulting, acting as a demand aggregator, will get supply of power through tariff based competitive bidding. The utilities that have evinced interest for scheme are Gujarat Urja Vikas Nigam Ltd (1000MW), Maharashtra State Electricity Distribution Company Ltd (500MW), Madhya Pradesh Power Management Company Ltd (660MW), New Delhi Municipal Corporation (250MW), and Tamil Nadu Generation and Distribution Corporation Ltd (1500MW). An official said that more states are likely to join the scheme and therefore the quantum of power supply has been kept higher at 4,500 MW. The supply of power under the power purchase agreement for medium term or five years must begin in April, 2023. The last date for the bid submission is December 21, 2022. After completing the bidding procedure the letter of award for supply of power would be given in January, 2023. The official said that the move would help the states that are facing power shortage and also help generation plants add capacities.

Glenmark Pharma inks settlement pact with Pfizer for cancer drug

Glenmark Pharmaceuticals on Tuesday said it has entered into a settlement agreement with Pfizer Inc regarding a cancer treatment drug. The Mumbai-based drug maker and its US-based unit have inked a settlement pact with drug major Pfizer Inc for Axitinib Tablets (1 mg and 5 mg). Glenmark's product is the generic version of Pfizer's Inlyta tablets, used to treat kidney cancer. According to IQVIATM sales data for the 12-month period ending September 2022, the Inlyta tablets (1 mg and 5 mg) achieved annual sales of around USD 644.5 million. Glenmark said its current portfolio consists of 177 products authorised for distribution in the US marketplace and 47 abbreviated new drug applications (ANDA's) are pending for approval with the US Food and Drug Administration.



Steel Strip Wheels to set up EV joint venture with Israel's Redler Technologies

Auto component maker Steel Strip Wheels Ltd has entered into a pact to form a joint venture with Israel's Redler Technologies for development, manufacturing and sales of motion controllers for electric vehicles in India. The two companies have signed a memorandum of understanding for the same and will collaborate on EV controllers for two-, three- and four-wheelers. The association will synergise the company's manufacturing capability, large consumer access and strong Indian presence with Redler's access to advanced technology. While Steel Strip Wheels is an automotive wheel maker, Redler is into design, development and production of servo motion control systems, intelligent circuit breakers and power distribution systems.



CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.					
Company	Details				
Hindustan Zinc Ltd	Cash dividend of INR15.5 effective 23-11-2022				
Indian Toners & Developers Ltd	Cash dividend of INR3.50 effective 23-11-2022				
Panama Petrochem Ltd	Cash dividend of INR3 effective 23-11-2022				
Maharashtra Seamless Ltd	Stock dividend of INR2 effective 23-11-2022				
Procter & Gamble Health Ltd	Corporate meeting effective 23-11-2022				

Domestic Events

No events

Global Events

- The U.K. S&P Global Manufacturing PMI Flash for November 2022.
- The U.S. Durable Goods Orders for October 2022.
- The U.S. MBA Mortgage Applications for November 18, 2022.
- The U.S. New Home Sales for October 2022.
- The U.S. Initial Jobless Claims November 19, 2022.
- Euro Area S&P Global Manufacturing PMI Flash for November 2022.

Source of News: The content may have been taken from The Economic Times, Business Standard, Business Line, Mint and other leading financial newspapers and financial portals BSE,NSE, Bloomberg, Moneycontrol & others.

Analyst Certification:

We /I, Jaydeb Dey Research Analyst(S) of SMIFS Limited (in short "SMIFS / the Company"), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document



to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independednt views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.



SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or comanaging public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.nseindi

SMIFS submit's that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.



Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

Contact us:

SMIFS Limited. (https://www.smifs.com/)

Compliance Officer:

Sudipto Datta,

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: compliance@smifs.com